Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy
Wei
Du
a,
Chen
Chen
a,
Peng
Sun
b,
Shengchang
Zhang
a,
Jing
Zhang
a,
Xiaoyu
Zhang
a,
Ying
Liu
a,
Rui
Zhang
a,
Chongzheng
Yan
a,
Changchun
Fan
c,
Jibiao
Wu
d and
Xinyi
Jiang
*a
aDepartment of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan, Shandong Province 250012, PR China. E-mail: xinyijiang@sdu.edu.cn; Fax: +86-0531-88382015; Tel: +86-0531-88382015
bCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China
cShandong Provincial Qianfoshan Hospital, the First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong 250014, PR China
dLaboratory of Traditional Chinese Medicine Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan, China
First published on 13th October 2022
Abstract
Correction for ‘Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy’ by Wei Du et al., Nanoscale, 2020, 12, 3317–3329, https://doi.org/10.1039/C9NR09835F.
The authors regret that the HMGB1 and merge images for 1-MT in Fig. 4d of the original article were incorrect, due to an error when preparing the manuscript. Additionally, the original caption of Fig. 4 did not make clear the repeated number ‘n’ for each experiment. The corrected Fig. 4, with an updated caption, is displayed below.
 | ||
| Fig. 4 ICD of tumor cells induced by OXA in vitro. (a) Schematic diagram of OXA-induced tumor cell ICD facilitating DC maturation through HMGB1 release, CRT exposure and ATP secretion. (b) CLSM examination, the cell nucleus, surface membrane and CRT were detected by Hoechst 33342, PKH-67, and Alexa Fluor® 647-conjugated anti-CRT antibody, respectively, and (c) quantitative examination of CRT exposure (n = 3). (d) CLSM test and (e) quantitative ELISA examination of HMGB1 release (n = 3). Scale bars, 20 μm. (f) NK-DNH induced a rapid release of ATP (n = 3). (g) In vitro maturation of DC (CD80+ and CD86+) induced by tumor cells with different treatment and (h) frequency of matured DC (n = 4). (The data are expressed as mean ± SD. **p < 0.01.) | ||
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2022 |